Leucovorin calcium/Levoleucovorin

Phase 3Small molecule

Leucovorin calcium/Levoleucovorin is one of 47 small molecule programs targeting Colorectal Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CancerActive, not recruiting

Colorectal NeoplasmsRecruiting

Colorectal CancerPhase 3

Active, not recruiting

Colorectal NeoplasmsPhase 3

Recruiting

Competition

Competitive Landscape

949 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Leucovorin calcium/Levoleucovorin

Johnson & Johnson

Phase 3

2 2

Eylea

Regeneron

Preclinical

5 3

PORTRAZZA

Eli Lilly

Preclinical

—4

Ketalar

AAultman Health Foundation

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

Gas-X

PPortuguese Oncology Institute, Coimbra

Preclinical

1 7

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 8

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 9

Bridion

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 10

Andriol

AAuxilium

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 3Recruiting

Colorectal Neoplasms

NCT06750094

Q1 2032

Phase 3Recruiting

Colorectal Neoplasms

NCT06662786

Clinical

Trials by Indication[1]

Colorectal Neoplasms2 trials

A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT06662786·1,000 enrolled

A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT06750094·700 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Leucovorin calcium/Levoleucovorin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Leucovorin calcium/Levoleucovorin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Leucovorin calcium/Levoleucovorin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson

Leucovorin calcium/Levoleucovorin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Q1 2032

Trials by Indication[1]

Colorectal Neoplasms2 trials

References

Drug Info

Quick Facts

Related News